DK2616069T3 - Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol - Google Patents

Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol Download PDF

Info

Publication number
DK2616069T3
DK2616069T3 DK11760963.6T DK11760963T DK2616069T3 DK 2616069 T3 DK2616069 T3 DK 2616069T3 DK 11760963 T DK11760963 T DK 11760963T DK 2616069 T3 DK2616069 T3 DK 2616069T3
Authority
DK
Denmark
Prior art keywords
methyl
ethyl
imidazol
benzyl ester
acid
Prior art date
Application number
DK11760963.6T
Other languages
English (en)
Inventor
Ken Chow
Mohammed I Dibas
John E Donello
Michael E Garst
Daniel W Gil
Liming Wang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2616069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2616069T3 publication Critical patent/DK2616069T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (6)

1. Forbindelse udvalgt fra følgende forbindelser eller farmaceutisk acceptabelt salt deraf: iso-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2.2- dimethyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; eddikesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-amino-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-amino-3-methyl-butyrylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4yl)-ethyl]-2-methyl-benzylester; 2-(2-amino-acetylamino)-3-methyl-smørsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2methyl-benzylester og 2- amino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester.
2. Forbindelse udvalgt fra følgende forbindelser eller farmaceutisk acceptabelt salt deraf: iso-smørsyre 3-[(S)-l-(l-iso-butyryl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2.2- dimethyl-propionsyre 3-{(S)-l-[l-(2,2-dimethyl-propiony)-lH-imidazol-4-yl]ethyl>-2-methyl-benzylester; eddikesyre 3-[(S)-l-(l-acetyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; benzoesyre 3-[(S)-l-(l-benzoyl-lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 3- methyl-smørsyre 2-methyl-3-{(S)-l-[l-(3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-benzylester; phenyl-propionsyre 2-methyl-3-{(S)-l-[l-(3-phenyl-propiony)-l/-/-imidazol-4-yl]ethyl}-benzylester; 2-tert-butoxycarbonylamino-3-methyl-smørsyre 3-{(S)-l-[l-(2-teri--butoxy carbonylamino-3-methyl-butyryl)-lH-imidazol-4-yl]-ethyl}-2-methyl- benzylester; 2-tert-butoxycarbonylamino-3-methyl-smørsyre 3-((S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl- smørsyre {(S)-l-[l-(2-terf--butoxycarbonylamino-3-methyl-butyryl)-lAV- imidazol-4-yl]-ethyl}-2methyl-benzylester; 2-(2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-3-methyl-smørsyre 3[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester; 2-(2-tert-butoxycarbonylamino-acetylamino)-3-methyl-smørsyre 3-[(S)- 1- (lHimidazol-4-yl)-ethyl]-2-methyl-benzylester og 2- tert-butoxycarbonylamino-3-phenyl-propionsyre 3-[(S)-l-(lH-imidazol-4-yl)-ethyl]-2-methyl-benzylester.
3. Farmaceutisk sammensætning omfattende en forbindelse eller farmaceutisk acceptabelt salt deraf som defineret i krav 1.
4. Forbindelse eller farmaceutisk acceptabelt salt deraf som defineret i krav 1 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af en tilstand eller en sygdom, der Undres af alpha 2A-, 2B-, 2C-aktivering, hvilken tilstand eller sygdom er udvalgt fra glaukom, forhøjet intraokulært tryk, iskæmisk neuropati, optisk neuropati, smerte, en retinal degenerativ tilstand, såsom diabetisk retinopati, apopleksi, en kognitiv svækkelse, en neuropsykiatrisk tilstand, lægemiddelafhængighed og -misbrug, abstinenssymptomer, obsessiv-kompulsiv tilstand, fedme, insulinresistens, en stress-relateret tilstand, diarre, diurese, nasal kongestion, spasticitet, ADHD, psykoser, angst, depression, autoimmun sygdom, Crohns sygdom, gastritis, en neurodegenerativ sygdom, såsom Alzheimers sygdom, Parkinsons sygdom og ALS, akne, aldersrelateret makuladedegeneration, våd makuladedegeneration, tør makuladedegeneration, geografisk atrofi, diabetisk makulaødem, en tumor, et sår, inflammation og retinal veneokklusion, synstab, såsom grundet glaukom, retinitis pigmentosa eller neuritis sekundær til multipel sklerose, rosacea (udvidelse af blodkar lige under huden), solforbrænding, kronisk solskade, diskret erytem, psoriasis, menopause-forbunden hedeture, hedeture som følge af orchiektomi-atopisk dermatitis, fotoældning, seborrhoisk dermatitis, allergisk dermatitis, huderytem (rødmen), telangiektasi (udvidelser af tidligere eksisterende små blodkar) i ansigtet, rhinophyma (hypertrofi af næsen med follikeludvidelse), rød bulbøs næse, akne-lignende hududbrud, brændende eller svidende fornemmelse i ansigtet, irriterede og blodskudte og løbende øjne, kutan hyperaktivitet med udvidelse af blodkar i huden, Lyells syndrom, Stevens-Johnson-syndrom, erythema multiforme minor og erythema multiforme major.
5. Farmaceutisk sammensætning ifølge krav 3 til anvendelse i en fremgangsmåde til behandling eller forebyggelse afen tilstand eller sygdom, der er udvalgt fra de tilstande eller sygdomme, der er defineret i krav 4.
6. Sammensætning eller salt deraf til anvendelse ifølge krav 4 eller farmaceutisk sammensætning til anvendelse ifølge krav 5, hvor smerten er udvalgt fra visceral smerte, hornhindesmerte, hovedpinesmerte, migrænesmerte, cancersmerte, rygsmerte, smerte ved irritabel tarmsyndrom, muskelsmerte og smerte forbundet med diabetisk neuropati.
DK11760963.6T 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol DK2616069T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
PCT/US2011/052004 WO2012037499A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol

Publications (1)

Publication Number Publication Date
DK2616069T3 true DK2616069T3 (da) 2016-12-19

Family

ID=44675870

Family Applications (9)

Application Number Title Priority Date Filing Date
DK16161921.8T DK3078376T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK19194325.7T DK3636263T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK16161922.6T DK3053576T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760962.8T DK2616068T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760963.6T DK2616069T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
DK16161923T DK3050564T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK18160174.1T DK3348264T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK18157147.2T DK3338777T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161920.0T DK3050563T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DK16161921.8T DK3078376T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK19194325.7T DK3636263T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK16161922.6T DK3053576T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK11760962.8T DK2616068T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK16161923T DK3050564T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]-methanol
DK18160174.1T DK3348264T3 (da) 2010-09-16 2011-09-16 Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til sænkning af intraokulært tryk
DK18157147.2T DK3338777T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
DK16161920.0T DK3050563T3 (da) 2010-09-16 2011-09-16 Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af hudsygdomme og -tilstande

Country Status (29)

Country Link
US (9) US8492422B2 (da)
EP (13) EP3050564B1 (da)
JP (4) JP2013541527A (da)
KR (7) KR101952457B1 (da)
CN (5) CN105412092B (da)
AR (4) AR083019A1 (da)
AU (4) AU2011301856C1 (da)
BR (4) BR112013006320B1 (da)
CA (8) CA2811559A1 (da)
CL (4) CL2013000733A1 (da)
CY (3) CY1121024T1 (da)
DK (9) DK3078376T3 (da)
ES (10) ES2760920T3 (da)
HK (5) HK1185540A1 (da)
HU (5) HUE049573T2 (da)
IL (4) IL225280A0 (da)
MX (4) MX2013003002A (da)
MY (4) MY173846A (da)
NZ (1) NZ608751A (da)
PL (7) PL2616069T3 (da)
PT (7) PT3050563T (da)
RU (4) RU2013116403A (da)
SG (4) SG188571A1 (da)
SI (5) SI3348264T1 (da)
TR (1) TR201909249T4 (da)
TW (4) TW201240662A (da)
UA (1) UA112973C2 (da)
WO (4) WO2012037453A1 (da)
ZA (4) ZA201302193B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241553B1 (en) 2009-02-13 2019-04-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112661772B (zh) * 2018-08-24 2022-06-10 杭州阿诺生物医药科技有限公司 干扰素基因刺激蛋白化合物及其制备方法
WO2022221071A1 (en) * 2021-04-16 2022-10-20 Ads Therapeutics Llc Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
WO2024167962A1 (en) * 2023-02-08 2024-08-15 Whitecap Biosciences Llc Alpha-2-adrenergic agonists for improving vision

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
JP2007528020A (ja) * 2003-07-14 2007-10-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 投影装置
EP2335734A3 (en) * 2003-09-12 2012-01-11 Allergan, Inc. Treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
MXPA06013649A (es) 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1797043A1 (en) 2004-09-24 2007-06-20 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
JP2012517433A (ja) 2009-02-06 2012-08-02 アラーガン インコーポレイテッド アルファ2bおよび/またはアルファ2cアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物
EP3241553B1 (en) 2009-02-13 2019-04-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Also Published As

Publication number Publication date
MY168763A (en) 2018-12-04
US8501796B2 (en) 2013-08-06
PL3348264T3 (pl) 2020-08-24
MX2013003004A (es) 2013-06-28
DK3636263T3 (da) 2022-01-10
EP3348264B1 (en) 2020-01-01
UA112973C2 (uk) 2016-11-25
PL2616068T3 (pl) 2016-11-30
EP2616066A1 (en) 2013-07-24
SG188570A1 (en) 2013-04-30
EP3636263B1 (en) 2021-11-03
KR20140003407A (ko) 2014-01-09
CA2812195A1 (en) 2012-03-22
PT2616068T (pt) 2016-09-13
US20130289088A1 (en) 2013-10-31
US20160354346A1 (en) 2016-12-08
EP3698789A1 (en) 2020-08-26
KR102354097B1 (ko) 2022-01-20
HUE039090T2 (hu) 2018-12-28
ES2613509T3 (es) 2017-05-24
EP2616067B1 (en) 2016-05-18
EP3053576B1 (en) 2018-05-16
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
TW201305117A (zh) 2013-02-01
EP3348264A1 (en) 2018-07-18
AU2011301901B2 (en) 2016-02-11
US20120136036A1 (en) 2012-05-31
IL225281A0 (en) 2013-06-27
KR20200044147A (ko) 2020-04-28
ZA201302193B (en) 2013-11-27
ES2593612T3 (es) 2016-12-12
RU2612351C2 (ru) 2017-03-07
WO2012037453A1 (en) 2012-03-22
ES2607084T3 (es) 2017-03-29
MX2013003009A (es) 2013-06-28
PT2616069T (pt) 2016-12-06
JP2013540749A (ja) 2013-11-07
RU2013116541A (ru) 2014-10-27
PL2616069T3 (pl) 2017-04-28
KR20200091507A (ko) 2020-07-30
PT3348264T (pt) 2020-04-02
ZA201302291B (en) 2013-11-27
RU2013116403A (ru) 2014-10-27
PL3050563T3 (pl) 2018-12-31
EP3636263A1 (en) 2020-04-15
CL2013000736A1 (es) 2013-07-12
PT3050563T (pt) 2018-10-01
HUE038698T2 (hu) 2018-11-28
PL3338777T3 (pl) 2020-07-13
ES2904479T3 (es) 2022-04-05
TW201240662A (en) 2012-10-16
KR101952457B1 (ko) 2019-02-26
SI3053576T1 (sl) 2018-11-30
EP2616068A1 (en) 2013-07-24
US8492422B2 (en) 2013-07-23
CA2811559A1 (en) 2012-03-22
CY1121024T1 (el) 2019-12-11
CA3122745A1 (en) 2012-03-22
EP3053576A1 (en) 2016-08-10
CL2013000735A1 (es) 2013-11-29
DK3078376T3 (da) 2019-06-24
AU2011301847A1 (en) 2013-05-02
CN105412092A (zh) 2016-03-23
US20130296394A1 (en) 2013-11-07
TW201305116A (zh) 2013-02-01
CA2812197A1 (en) 2012-03-22
EP3050563A1 (en) 2016-08-03
AR083018A1 (es) 2013-01-23
NZ608751A (en) 2015-04-24
BR112013006352A2 (pt) 2016-06-28
BR112013006355A2 (pt) 2016-06-28
KR101840500B1 (ko) 2018-03-20
AU2011301901A1 (en) 2013-05-02
JP2013537237A (ja) 2013-09-30
BR112013006320A2 (pt) 2016-06-21
SI3050563T1 (sl) 2018-10-30
JP2013541527A (ja) 2013-11-14
EP3050564B1 (en) 2019-09-04
CN103200941B (zh) 2015-12-16
EP3338777B1 (en) 2020-02-05
PL3050564T3 (pl) 2020-06-01
EP2616069B1 (en) 2016-11-16
CL2013000734A1 (es) 2013-11-08
CY1122809T1 (el) 2021-05-05
DK3348264T3 (da) 2020-03-23
CA2812191C (en) 2021-04-13
DK2616068T3 (da) 2016-08-29
PT3338777T (pt) 2020-05-06
HUE047476T2 (hu) 2020-04-28
KR102139905B1 (ko) 2020-07-31
WO2012037484A1 (en) 2012-03-22
MY191369A (en) 2022-06-20
EP2616069A1 (en) 2013-07-24
EP3338777A1 (en) 2018-06-27
EP3050564A1 (en) 2016-08-03
US20120142746A1 (en) 2012-06-07
CN103200941A (zh) 2013-07-10
SG188573A1 (en) 2013-04-30
EP2616067A1 (en) 2013-07-24
PL3053576T3 (pl) 2018-11-30
JP6073229B2 (ja) 2017-02-01
TR201909249T4 (tr) 2019-07-22
KR20130114140A (ko) 2013-10-16
KR101840501B1 (ko) 2018-05-04
HK1185541A1 (zh) 2014-02-21
US8492557B2 (en) 2013-07-23
AU2011301932A1 (en) 2013-05-02
CA3079450A1 (en) 2012-03-22
CY1122958T1 (el) 2021-10-29
ES2687420T3 (es) 2018-10-25
IL225280A0 (en) 2013-06-27
US20120149746A1 (en) 2012-06-14
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
IL225282A0 (en) 2013-06-27
HK1185539A1 (zh) 2014-02-21
BR112013006320B1 (pt) 2022-08-30
AU2011301932C1 (en) 2016-09-01
AR083019A1 (es) 2013-01-23
CN103209694A (zh) 2013-07-17
DK3338777T3 (da) 2020-04-20
ES2788051T3 (es) 2020-10-20
EP3050563B1 (en) 2018-05-09
US20140057958A1 (en) 2014-02-27
CN105412092B (zh) 2020-11-17
ES2737230T3 (es) 2020-01-10
SG188571A1 (en) 2013-04-30
MX2013003008A (es) 2013-06-28
EP3078376A1 (en) 2016-10-12
IL225278A (en) 2015-11-30
US8853251B2 (en) 2014-10-07
KR102104760B1 (ko) 2020-04-27
SG188572A1 (en) 2013-04-30
HK1185538A1 (zh) 2014-02-21
CL2013000733A1 (es) 2013-08-23
SI3050564T1 (sl) 2020-02-28
AR083020A1 (es) 2013-01-23
WO2012037499A1 (en) 2012-03-22
DK3050564T3 (da) 2019-11-25
ES2760920T3 (es) 2020-05-18
JP2013537236A (ja) 2013-09-30
AU2011301847B2 (en) 2016-02-11
US8653123B2 (en) 2014-02-18
MY173846A (en) 2020-02-24
EP2616066B1 (en) 2016-07-13
WO2012037490A1 (en) 2012-03-22
DK3053576T3 (da) 2018-08-20
ES2781681T3 (es) 2020-09-04
US20120122945A1 (en) 2012-05-17
ES2684055T3 (es) 2018-10-01
CA3077732A1 (en) 2012-03-22
CA3116249A1 (en) 2012-03-22
IL225278A0 (en) 2013-06-27
PT3050564T (pt) 2019-12-11
AU2011301856A1 (en) 2013-05-02
AU2011301932B2 (en) 2016-02-25
MY161607A (en) 2017-04-28
ZA201302288B (en) 2013-11-27
RU2013116405A (ru) 2014-10-27
TW201240661A (en) 2012-10-16
SI3348264T1 (sl) 2020-07-31
DK3050563T3 (da) 2018-08-13
KR20190022895A (ko) 2019-03-06
US20150148394A1 (en) 2015-05-28
KR20140005154A (ko) 2014-01-14
HK1257416A1 (zh) 2019-10-18
HUE049573T2 (hu) 2020-10-28
EP3078376B1 (en) 2019-03-27
AU2011301856C1 (en) 2016-09-08
CA2812191A1 (en) 2012-03-22
TWI591058B (zh) 2017-07-11
CN103221045A (zh) 2013-07-24
HUE048725T2 (hu) 2020-09-28
CA2812197C (en) 2024-01-02
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
MX2013003002A (es) 2013-06-28
PT3053576T (pt) 2018-10-08
SI3338777T1 (sl) 2020-08-31
EP3659600A1 (en) 2020-06-03
CN103200942A (zh) 2013-07-10
JP6045495B2 (ja) 2016-12-14
ZA201302194B (en) 2013-11-27

Similar Documents

Publication Publication Date Title
DK2616069T3 (da) Ester pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
AU2011301856B2 (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol